RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies

References

• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–7360.
   PubMed Web of Science ®Google Scholar
• Smolarek AK, Suh N. Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol. Nutrients. 2011;3:962–986.
   PubMed Web of Science ®Google Scholar
• Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157–167.
   PubMed Web of Science ®Google Scholar
• Linn SC, Van’t Veer LJ. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer. 2009;45:11–26.
   PubMedGoogle Scholar
• Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1–10.
   PubMed Web of Science ®Google Scholar
• Radia A-M, Yaser A-M, Ma X, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci. 2013;14:7959–7978.
   PubMed Web of Science ®Google Scholar
• You S, Li W. Administration of nanodrugs in proper menstrual stage for maximal drug retention in breast cancer. Med Hypotheses. 2008;71:141–147.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–150.
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt A, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–15004.
   PubMed Web of Science ®Google Scholar
• Hsieh H-L, Schäfer BW, Sasaki N, et al. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun. 2003;307:375–381.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Fritz G, Vetter SW, et al. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta. 2009;1793:993–1007.
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4:285–293.
   PubMedGoogle Scholar
• Wu X, Mi Y, Yang H, et al. The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway. Mol Cell Biochem. 2013;380:249–257.
   PubMed Web of Science ®Google Scholar
• Nasser MW, Wani NA, Ahirwar DK, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015;75:974–985.
   PubMed Web of Science ®Google Scholar
• Yeh C-H, Sturgis L, Haidacher J, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes. 2001;50:1495–1504.
   PubMed Web of Science ®Google Scholar
• Lata K, Mukherjee TK. Knockdown of receptor for advanced glycation end products attenuate 17α-ethinyl-estradiol dependent proliferation and survival of MCF-7 breast cancer cells. Biochim Biophys Acta. 2014;1840:1083–1091.
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Karri VVSR, et al. Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:474–488.
   PubMed Web of Science ®Google Scholar
• Tummala S, Kumar MS, Pindiprolu SK. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles. Drug Deliv. 2016;23:3505–3519.
   PubMed Web of Science ®Google Scholar
• Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One. 2012;7:e32920.
   PubMed Web of Science ®Google Scholar
• Zhang X-G, Miao J, Dai Y-Q, et al. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm. 2008;361:239–244.
   PubMed Web of Science ®Google Scholar
• Venkata Siddhartha T, Senthil V, Sai Kishan I, et al. Design and development of oral nanoparticulated insulin in multiple emulsion. Curr Drug Deliv. 2014;11:472–485.
   PubMed Web of Science ®Google Scholar
• Talluri S, Pindiprolu S, Janarthanam R, Kuppusamy G, editors. Development and efficacy evaluation of smart nanocarriers for targeting breast cancers. Eur J Cancer. 2016;57:S122.
   Google Scholar
• Hu F-Q, Jiang S-P, Du Y-Z, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 2005;45:167–173.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, et al. Folate-modified lipid–polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine. 2015;10:2101.
   PubMed Web of Science ®Google Scholar
• Sharma G, Park J, Sharma AR, et al. Methoxy Poly (ethylene glycol)-Poly (lactide) nanoparticles encapsulating quercetin act as an effective anticancer agent by inducing apoptosis in breast cancer. Pharm Res. 2015;32:723–735.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–1116.
   PubMed Web of Science ®Google Scholar
• Chen R, Wang S, Zhang J, et al. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study. Drug Deliv. 2015;22:666–674.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465.
   PubMed Web of Science ®Google Scholar
• Panyam J, ZHOU W-Z, PRABHA S, et al. Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16:1217–1226.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52:891–896.
   PubMed Web of Science ®Google Scholar
• Elumalai P, Gunadharini D, Senthilkumar K, et al. Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett. 2012;215:131–142.
   PubMed Web of Science ®Google Scholar
• Gillings AS, Balmanno K, Wiggins CM, et al. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J. 2009;276:6050–6062.
   PubMed Web of Science ®Google Scholar
• Lee J-E, Lee R-A, Kim K-H, et al. Induction of apoptosis with diallyl disulfide in AGS gastric cancer cell line. J Korean Surg Soc. 2011;81:85–95.
   PubMedGoogle Scholar